To evaluate objective response rate and duration of response to weekly Taxoprexin®.
To evaluate the safety profile of weekly Taxoprexin® in this patient population.
To evaluate overall survival in the same patient population. To evaluate time to disease
progression, and the time to treatment failure in patients with metastatic malignant melanoma
being treated with weekly Taxoprexin® Injection.